Robert M. DiPardo

3.6k total citations · 1 hit paper
57 papers, 2.7k citations indexed

About

Robert M. DiPardo is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Robert M. DiPardo has authored 57 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 25 papers in Cellular and Molecular Neuroscience and 16 papers in Organic Chemistry. Recurrent topics in Robert M. DiPardo's work include Neuropeptides and Animal Physiology (21 papers), Chemical Synthesis and Analysis (12 papers) and Receptor Mechanisms and Signaling (10 papers). Robert M. DiPardo is often cited by papers focused on Neuropeptides and Animal Physiology (21 papers), Chemical Synthesis and Analysis (12 papers) and Receptor Mechanisms and Signaling (10 papers). Robert M. DiPardo collaborates with scholars based in United States and United Kingdom. Robert M. DiPardo's co-authors include Mark G. Bock, Roger Freidinger, B. Evans, Kenneth E. Rittle, Daniel F. Veber, Willie L. Whitter, Paul Anderson, Raymond S.L. Chang, James P. Springer and G. F. Lundell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Controlled Release.

In The Last Decade

Robert M. DiPardo

56 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

1988 1.2k citations B. Evans, Kenneth E. Rittle et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert M. DiPardo United States	21	1.5k	1.4k	680	260	228	57	2.7k
Kenneth E. Rittle United States	20	1.3k 0.9×	1.3k 1.0×	585 0.9×	278 1.1×	213 0.9×	38	2.5k
William J. Greenlee United States	34	2.2k 1.5×	2.0k 1.4×	642 0.9×	338 1.3×	251 1.1×	161	4.5k
Mark G. Bock United States	29	1.9k 1.3×	1.8k 1.3×	875 1.3×	326 1.3×	330 1.4×	109	3.8k
B. Evans United States	21	1.6k 1.1×	1.4k 1.0×	660 1.0×	264 1.0×	232 1.0×	56	2.9k
Raymond S.L. Chang United States	31	2.7k 1.9×	1.6k 1.2×	1.6k 2.3×	374 1.4×	277 1.2×	114	4.7k
H. Timmerman Netherlands	26	1.5k 1.1×	614 0.4×	477 0.7×	286 1.1×	167 0.7×	91	3.1k
Donald S. Karanewsky United States	30	1.8k 1.2×	1.1k 0.8×	218 0.3×	145 0.6×	362 1.6×	77	3.0k
Paola Fossa Italy	30	1.2k 0.8×	1.2k 0.9×	357 0.5×	328 1.3×	140 0.6×	136	2.6k
Shaun R. Stauffer United States	35	1.9k 1.3×	1.4k 1.0×	1.1k 1.6×	249 1.0×	230 1.0×	96	4.2k
Willie L. Whitter United States	13	1.1k 0.8×	1.0k 0.8×	528 0.8×	228 0.9×	178 0.8×	19	2.0k

Countries citing papers authored by Robert M. DiPardo

Since Specialization

Citations

This map shows the geographic impact of Robert M. DiPardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. DiPardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. DiPardo more than expected).

Fields of papers citing papers by Robert M. DiPardo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. DiPardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. DiPardo. The network helps show where Robert M. DiPardo may publish in the future.

Co-authorship network of co-authors of Robert M. DiPardo

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. DiPardo. A scholar is included among the top collaborators of Robert M. DiPardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. DiPardo. Robert M. DiPardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuduk, Scott D., Ronald K. Chang, Christina N. Di Marco, et al.. (2011). Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3). Bioorganic & Medicinal Chemistry Letters. 21(14). 4255–4258. 16 indexed citations

Kuduk, Scott D., Robert M. DiPardo, Douglas C. Beshore, et al.. (2010). Hydroxy cycloalkyl fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20(8). 2538–2541. 15 indexed citations

Kuduk, Scott D., Ronald K. Chang, Robert M. DiPardo, et al.. (2008). Bradykinin B1 receptor antagonists: An α-hydroxy amide with an improved metabolism profile. Bioorganic & Medicinal Chemistry Letters. 18(18). 5107–5110. 21 indexed citations

Feng, Dong-Mei, Robert M. DiPardo, Jenny Wai, et al.. (2007). A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity. Bioorganic & Medicinal Chemistry Letters. 18(2). 682–687. 15 indexed citations

Conley, Rachel K., Alan Wheeldon, J.K. Webb, et al.. (2005). Inhibition of acute nociceptive responses in rat spinal cord by a bradykinin B1 receptor antagonist. European Journal of Pharmacology. 527(1-3). 44–51. 7 indexed citations

Hess, J. Fred, Richard W. Ransom, Zhizhen Zeng, et al.. (2004). Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model. Journal of Pharmacology and Experimental Therapeutics. 310(2). 488–497. 19 indexed citations

DiPardo, Robert M., Michael A. Patane, Theodore P. Broten, et al.. (2001). Cyclic imides as potent and selective α-1A adrenergic receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 11(14). 1959–1962. 6 indexed citations

Patane, Michael A., Robert M. DiPardo, Theodore P. Broten, et al.. (2000). Phenylacetamides as selective α-1A adrenergic receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 10(15). 1621–1624. 8 indexed citations

Patane, Michael A., Robert M. DiPardo, Richard W. Ransom, et al.. (1998). Selective α-1A adrenergic receptor antagonists. effects of pharmacophore regio- and stereochemistry on potency and selectivity. Bioorganic & Medicinal Chemistry Letters. 8(18). 2495–2500. 26 indexed citations

10.

Freedman, Stephen B., Smita S. Patel, Alesha Smith, et al.. (1994). A Second Generation of Non‐Peptide Cholecystokinin Receptor Antagonists and Their Possible Therapeutic Potential. Annals of the New York Academy of Sciences. 713(1). 312–318. 8 indexed citations

11.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1994). ChemInform Abstract: Development of 1,4‐Benzodiazepine Cholecystokinin Type B Antagonists.. ChemInform. 25(26). 3 indexed citations

12.

Evans, B., James L. Leighton, Kenneth E. Rittle, et al.. (1992). Orally active, nonpeptide oxytocin antagonists. Journal of Medicinal Chemistry. 35(21). 3919–3927. 64 indexed citations

13.

Bock, Mark G., Robert M. DiPardo, Paul Williams, et al.. (1990). Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide. Journal of Medicinal Chemistry. 33(9). 2321–2323. 26 indexed citations

14.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1990). Cholecystokinin-A receptor ligands based on the .kappa.-opioid agonist tifluadom. Journal of Medicinal Chemistry. 33(1). 450–455. 16 indexed citations

15.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1989). Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260. Journal of Medicinal Chemistry. 32(1). 13–16. 250 indexed citations

16.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1988). Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines. Journal of Medicinal Chemistry. 31(1). 176–181. 16 indexed citations

17.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1988). Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines. Journal of Medicinal Chemistry. 31(1). 264–268. 18 indexed citations

18.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1987). Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini. Journal of Medicinal Chemistry. 30(10). 1853–1857. 9 indexed citations

19.

Rittle, Kenneth E., B. Evans, Mark G. Bock, et al.. (1987). A new amine resolution method and its application to 3-aminobenzodiazepines. Tetrahedron Letters. 28(5). 521–522. 20 indexed citations

20.

Bock, Mark G., et al.. (1985). ChemInform Abstract: SYNTHESIS OF QUINAZOLINO(3,2‐D)‐1,4‐BENZODIAZEPIN‐6,9(5H,7H)‐DIONES. Chemischer Informationsdienst. 16(28). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact